Annual Drug Patent Expiration for HETLIOZ+LQ
Hetlioz Lq is a drug marketed by Vanda Pharms Inc and included in one NDA. It is available from a single supplier. There are fifteen patents protecting this drug.
Drug patent litigation for HETLIOZ LQ.
This drug has two hundred and two patent family members in thirty one countries.
The generic ingredient in HETLIOZ LQ is tacimelteon. One registered supplier for this compound. Additional details are available on the tasmelteon profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published in New patent for the drug Vanda Pharms HETLIOZ LQ